“We continue to make steady and significant progress across our pipeline,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We expect to report the first data from the CRB-701 U.S. bridging study in Q1 2025. This significant dataset will build on the encouraging clinical data presented at ASCO 2024 by CSPC, our development partner. The emerging efficacy and safety data presented at ASCO 2024 was promising and demonstrated the drug is clinically active with a differentiated safety profile. We are also pleased with the continued development of CRB-913, our highly peripherally restricted CB1 inverse agonist for the treatment of obesity. We presented updated pre-clinical data at Obesity Week 2024 and expect to dose the first study participant in Q1 2025,” concluded Dr. Cohen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Reveals Promising Obesity Treatment Data
- Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week
- CRBP Upcoming Earnings Report: What to Expect?
- Corbus Pharmaceuticals completes enrollment for Phase 1 trial of CRB-701
- Largest borrow rate increases among liquid names